期刊文献+

检测人乳腺癌MCF-7细胞在不同HER-2水平培养上清中miRNAs的表达谱 被引量:2

Expression profile of miRNAs in supernatant of cultured human breast cancer MCF-7 cells at different HER-2 levels
下载PDF
导出
摘要 目的检测不同人类表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)表达水平在人乳腺癌细胞培养上清中微小RNAs(miRNAs)的表达,初步筛选与HER-2表达相关的miRNAs表达谱。方法培养人乳腺癌细胞MCF-7和稳定转染HER-2的MCF-7(MCF-7/HER-2),分别收集2株细胞的培养上清,利用miRNAs芯片技术检测其miRNAs的表达,并与MCF-7和MCF-7/HER-2细胞中miRNAs表达谱进行对比。结果细胞培养上清中筛选138种与HER-2相关的miRNAs,较正常MCF-7细胞上调86个,下调52个。与细胞中筛选的miRNAs对比,同时上调与下调各有7种;在细胞培养上清液中上调而在细胞中下调的有1种;在细胞培养上清液中下调而在细胞中上调的有7种。结论不同HER-2水平的人乳腺癌细胞外泌miRNAs存在差异性表达。 Purpose To detect the expression of miRNAs in the supernatant of cultured human breast cancer cells with different human epidermalgrowth factor receptor-2 (HER-2) expression levels, and to preliminarily screen HER-2 expression related miRNAs profile. Methods Two human breast cancer cell strains, MCF-7 and MCF-7/HER-2 which is stably transfected by HER-2, were cultured. The expression profile of miRNAs in the supernatant and cultured cells were detected by miRNAs microarray analysis and compared. Results In the supematant of cultured eel]s, 138 kinds of miRNAs relevant to HER-2 were selected. Compare with HER-2-negative MCF-7 cells, 86 were up-regulated and 52 were down-regulated. Among those differentially expressed miRNAs, 7 of them were up-reg- ulated and 7 were down-regulated in the supernatant and the cells. Meanwhile, 1 up-regulated miRNA in the supernatant was down- regulated in the cells, and 7 down-regulated miRNAs in the supernatant were up-regulated in cells. Conclusion Differential excretion of miRNAs does exist in human breast cancer cells with different HER-2 levels.
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2016年第3期248-251,257,共5页 Chinese Journal of Clinical and Experimental Pathology
基金 国家自然科学基金面上项目资助(81372476) 安徽医科大学第二附属医院引进人才基金(2015yrcjj11)
关键词 乳腺肿瘤 培养上清 MIRNAS HER-2 breast neoplasm culture supernatant miRNAs HER-2
  • 相关文献

参考文献11

  • 1Noordhuis M G, Eijsink J J, Roossink F, et al. Prognostic cell bi- ological markers in cervical cancer patients primarily treated with (chemo) radiation: a systematic review [ J]. nt J Radiat Oncol Biol Phys, 2011,79(2) :325 -34.
  • 2Joensuu H, Bono P, Kataja V, et al. Fluorottracil, epirubicin, and cyelophosphamide with either docetaxel or orelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial [ J ]. Clin Oncol, 2009,27 (34) :5685 - 92.
  • 3Esquela-Kerscher A, Slack F J. Oncomirs-microRNAs with a role in cancer[ J]. Nat Rev Cancer, 2006,6(4) :259 -69.
  • 4Lowe A C, Pignon J C, Carvo I, et al. Young investigator chal- lenge: application of cytologic techniques to circulating tumor cell specimens : detecting activation of the oncogenic transcription factor STAT3 [J]. Cancer Cytopathol, 2015,123 (12) :696 - 706.
  • 5许成辰,朱桂璐,王弦,吴正升,吴强,秦蓉.人乳腺癌MCF-7细胞在不同HER-2水平miRNAs表达谱检测[J].临床与实验病理学杂志,2014,30(9):967-970. 被引量:1
  • 6沈国栋,杜锐凯,査昭,胡思怡,王弦,吴强,胡世莲,刘兢.人乳腺癌细胞MCF-7/HER2稳转株裸鼠移植瘤模型的建立[J].中国药理学通报,2013,29(4):588-589. 被引量:5
  • 7吴一龙.非小细胞肺癌血液EGFR基因突变检测中国专家共识[J].中华医学杂志,2015,95(46):3721-3726. 被引量:67
  • 8Bertoli G, Cava C, Castiglioni I. MicmRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer[J ]. Theranosties, 2015,5(10) :1122 -43.
  • 9Valadi H, Ekstrm K, Bossios A, et al. Exosome-mediated trans- fer of mRNAs and microRNAs is a novel mechanism of genetic ex- change between cells[ J]. Nat Cell Biol, 2007,9(6) :654 -9.
  • 10Ye X, Bai W, Zhu H, et al. MiR-221 promotes trastuzumab-resist- ance and metastasis in HER-2-positive breast cancers by targeting PTEN[J]. BMB Rep, 2014,47(5) :268 -73.

二级参考文献16

  • 1沈震宇,薛花,程联胜,吴强,刘兢,杨枫.p185高表达人卵巢癌裸鼠模型的建立[J].安徽医科大学学报,2005,40(4):300-301. 被引量:2
  • 2Gutierrez C, Schiff R.HER2: biology, detection, and clinical implications[J].Arch Pathol Lab Med, 2011,135(1):55-62.
  • 3Noordhuis M G, Eijsink J J, Roossink F, et al.Prognostic cell biological markers in cervical cancer patients primarily treated with(chemo) radiation: a systematic review[J].Int J Radiat Oncol Biol Phys, 2011,79(2):325-34.
  • 4Rodriguez G F, Sieuwerts A M, Smid M, et al.MicroRNA 30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer[J].Breast Cancer Res Treat, 2011,127(1):43-51.
  • 5Adachi R, Horiuchi S, Sakurazawa Y, et al.ErbB2 down-regulates microRNA205 in breast cancer[J].Biochen Biophys Res Commum, 2011,411(4):804-8.
  • 6Le X F, Almeida M I, Mao W, et al.Modulation of MicroRNA-194 and cell migration by HER-2-targeting trastuzumab in breast cancer[J].PLoS One, 2012,7(7):e41170.
  • 7Fang C, Zhao Y, Guo B.MiR-199b-5p targets HER2 in breast cancer cells[J].J Cell Biochem, 2013,114(7):1457-63.
  • 8Epis M R, Barker A, Giles K M, et al.The RNA-binding protein huR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostat cancer cells[J].J Biol Chem, 2011,286(48):41442-54.
  • 9Jin L, Wessely O, Marcusson E G, et al.Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNFα in breast cancer[J].Cancer Res, 2013,73(9):2884-96.
  • 10Shang C, Lu Y M, Meng L R.MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2[J].Med Sci Monit, 2012,18(4):149-55.

共引文献70

同被引文献9

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部